Close Menu

More articles about COVID-19

The company, known for providing hereditary risk testing for cancer and cardiovascular conditions, has expanded into SARS-CoV-2 testing.

The system is based on GNA's proprietary pulsed control amplification technology, which uses short electrical pulses to drive rapid amplification cycles.

The SARS-CoV-2 test, which runs on Cepheid's GeneXpert systems, is to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as nasal swabs.

The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated. 

Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.

The Solana SARS-CoV-2 test can be run in batches of 11 samples, with minimum hands on time, no extraction, and results in approximately 25 minutes.

Xprize said it selected the finalists from 219 semifinalists after conducting blind proficiency testing and judging a questionnaire reflecting each team's qualifications.

Bayer will offer Veracyte's Afirma Xpression Atlas to identify underlying drivers in tumors of late-stage or metastatic thyroid cancer patients resistant to radioactive iodine therapy.

The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.

An analysis of SARS-CoV-2 genomes from early COVD-19 patients in Scotland shows the virus was introduced there multiple times, typically from continental Europe.

The PCR-based test is designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens such as anterior nasal swabs collected by a healthcare provider.

Osang is seeking US Food and Drug Administration Emergency Use Authorization for its PCR-based SARS-CoV-2 diagnostic kit and plans to distribute it to US airports.

While SARS-CoV-2 test demand will likely remain strong well into 2021, the question of what to do with the built-up capacity in a post-COVID-19 environment looms.

Toronto-based DMark Biosciences will provide the UgenTec FastFinder PCR analysis software to molecular diagnostic labs across Canada.

The firm claims a rapid isothermal test has an LoD of 20 viral copies per milliliter while a saliva-based PCR test has an LoD of 2 copies per milliliter.

The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.

The companies will each contribute resources to the initiative, which is focused on increasing SARS-CoV-2 testing capacity in the Netherlands.

Genetworx and PacificDx's tests detect SARS-CoV-2 nucleic acid, while Hologic's test can also detect and differentiate SARS-CoV-2 and influenza A and B.

The agency also helped fund the development of the Revogene SARS-CoV-2 assay, which detects RNA targets directly from viral transport media without pre-dilution.

Diagnostics revenues were €32.5 million in Q3, up almost fivefold from €6.8 million last year, and included €27.4 million from commercial coronavirus testing.


The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.